You need to sign in or sign up before continuing.
HOUSE_OVERSIGHT_024835.jpg
1.88 MB
Extraction Summary
1
People
10
Organizations
3
Locations
0
Events
1
Relationships
2
Quotes
Document Information
Type:
Financial research report / industry analysis
File Size:
1.88 MB
Summary
This document is page 19 of a Cowen 'Collaborative Insights' report dated February 25, 2019. It details the industry landscape for synthetic biology cannabinoid production, listing specific companies such as Ginkgo Bioworks and Amyris with brief descriptions of their technologies. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a document production for a congressional investigation, though no direct mention of Jeffrey Epstein appears on this specific page.
People (1)
| Name | Role | Context |
|---|---|---|
| Michael Cella | Recipient/Authorized User |
Email address michael.cella@cowen.com appears in the right margin watermark indicating the report is intended for him.
|
Organizations (10)
| Name | Type | Context |
|---|---|---|
| Cowen |
Financial services firm publishing the report (Cowen Collaborative Insights).
|
|
| Cellibre |
Listed in Figure 10 as a cellular agriculture company.
|
|
| Ginkgo Bioworks |
Listed in Figure 10 as a microbe design company.
|
|
| Hyasynth Biologicals |
Listed in Figure 10 as a biology/computational analysis company.
|
|
| InMed Pharmaceuticals |
Listed in Figure 10 as a biopharmaceutical company.
|
|
| Librede |
Listed in Figure 10 as a yeast-based cannabinoid production company.
|
|
| Renew Biopharma |
Listed in Figure 10 as a company producing cannabinoids for neuroinflammation.
|
|
| Teewinot Life Sciences |
Listed in Figure 10 as a biosynthetic process company.
|
|
| Amyris |
Listed in Figure 10 as an industrial biotechnology company.
|
|
| House Oversight Committee |
Implied by the Bates stamp 'HOUSE_OVERSIGHT_024835'.
|
Relationships (1)
Email address domain @cowen.com and watermark stating report is intended for him.
Key Quotes (2)
"The many perceived advantages of synthetic cannabinoid creation have led to a series of companies entering the market"Source
HOUSE_OVERSIGHT_024835.jpg
Quote #1
"Synthetic biology methods use fermentation to produce cannabinoids with identical chemical structures to those found in plants."Source
HOUSE_OVERSIGHT_024835.jpg
Quote #2
Full Extracted Text
Complete text extracted from the document (3,477 characters)
COWEN
COLLABORATIVE INSIGHTS
February 25, 2019
COLLABORATIVE INSIGHTS
February 25, 2019
controls can be implemented when producing compounds with a biosynthesis method similar to the processes in place for pharmaceutical regulation.
The many perceived advantages of synthetic cannabinoid creation have led to a series of companies entering the market, as described below.
Figure 10 Selected Synthetic Biology Cannabinoid Companies
Company
Notes
Notes
Cellibre
Cellibre is a next-generation cellular agriculture company. Employing an organism-agnostic approach, Cellibre turns cells into specialized, sustainable factories for the manufacture of globally significant products at scale.
Cellibre is a next-generation cellular agriculture company. Employing an organism-agnostic approach, Cellibre turns cells into specialized, sustainable factories for the manufacture of globally significant products at scale.
Ginkgo Bioworks
Ginkgo is a Boston-based company that designs custom microbes for customers across multiple markets, developing new organisms that replace technology with biology.
Ginkgo is a Boston-based company that designs custom microbes for customers across multiple markets, developing new organisms that replace technology with biology.
Hyasynth Biologicals
Located in Montreal, Hyasynth Biologicals uses the technologies from traditional and modern biology combined with computational analysis to develop organisms at the fastest possible speed.
Located in Montreal, Hyasynth Biologicals uses the technologies from traditional and modern biology combined with computational analysis to develop organisms at the fastest possible speed.
InMed Pharmaceuticals
InMed Pharmaceuticals is a biopharmaceutical company that specializes in the discovery and development of novel, cannabinoid-based therapeutics for the treatment of diseases with high unmet medical need.
InMed Pharmaceuticals is a biopharmaceutical company that specializes in the discovery and development of novel, cannabinoid-based therapeutics for the treatment of diseases with high unmet medical need.
Librede
Librede has developed a yeast-based cannabinoid production and drug discovery platform to create chemical compounds that target the endocannabinoid system. Librede's modular technology enables large scale production of natural cannabinoids in a more economic and environmentally sustainable way
Librede has developed a yeast-based cannabinoid production and drug discovery platform to create chemical compounds that target the endocannabinoid system. Librede's modular technology enables large scale production of natural cannabinoids in a more economic and environmentally sustainable way
Renew Biopharma
Renew Biopharma harnesses the biological pathway to produce natural and novel cannabinoids that cross the blood brain barrier and target specific receptors associated with neuroinflammation and chronic pain.
Renew Biopharma harnesses the biological pathway to produce natural and novel cannabinoids that cross the blood brain barrier and target specific receptors associated with neuroinflammation and chronic pain.
Teewinot Life Sciences
Tampa-based Teewinot combines its biosynthetic processes with sophisticated chemical synthesis to produce proprietary cannabinoid analogs and prodrugs at commercial scale.
Tampa-based Teewinot combines its biosynthetic processes with sophisticated chemical synthesis to produce proprietary cannabinoid analogs and prodrugs at commercial scale.
Amyris
Amyris is an industrial biotechnology company that has used sugarcane fermentation to create hydrocarbon molecules and produces an array of specialty ingredients and consumer products.
Amyris is an industrial biotechnology company that has used sugarcane fermentation to create hydrocarbon molecules and produces an array of specialty ingredients and consumer products.
Source: Cowen and Company
Producing Cannabinoids Using Synthetic Biology
Synthetic biology methods use fermentation to produce cannabinoids with identical chemical structures to those found in plants.
Biocatalytic Cannabinoid Pathways
The first step of the synthetic cannabinoid production requires identification and extraction of the desired cannabinoid biosynthetic pathways from a cannabis varietal. The biosynthesis of cannabinoid molecules in a microbe could require four or more cannabinoid metabolic pathways. When the pathways are selected, their corresponding DNA sequences need to be cloned from the cannabis varietal and spliced into the microbial DNA.
Cannabinoids could be produced biocatalytically using the following mechanism:
i. In the first pathway, glucose is converted into G3P and pyruvate via glycolysis. These two compounds are then utilized to produce the precursors geranyl pyrophosphate (GPP), and/or neryl pyrophosphate (NPP).
ii. Glycolysis of glucose also produces Acetyl CoA, which can catalyze biosynthesis of the second group of precursors: olivetolic acid (OA) and divarinic acid (DVA).
COWEN.COM
19
HOUSE_OVERSIGHT_024835
19
HOUSE_OVERSIGHT_024835
[Right Margin Text] This report is intended for michael.cella@cowen.com. Unauthorized redistribution of this report is prohibited.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document